ReviewPediatric discovery2023
The association of soluble cluster of differentiation 36 with metabolic diseases: A potential biomarker and therapeutic target.
Review in Pediatric discovery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Silent Myocardial Infarction Revisited: Immuno-metabolic Mechanisms, Multimodal Biomarkers, and Translational Diagnostics.Journal of cardiovascular translational research · 2026Review
- The association of soluble cluster of differentiation 36 with metabolic diseases: A potential biomarker and therapeutic target.Pediatric discovery · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A cluster of differentiation 36 (CD36), also known as fatty acid translocase, plays an important role in developing and progressing metabolic diseases. Soluble CD36 (sCD36), a circulating form of CD36, is identified in human plasma. Current studies have demonstrated that sCD36 is an early biomarker of type 2 diabetes (T2DM) and atherosclerosis risk and may act as a key molecule in organ cross-talks directly or indirectly. This review summarizes the cell sources, molecular structure, potential production mechanism, functions, and regulators of sCD36. We highlight the association of sCD36 with hyperlipidemia, metabolic inflammation, T2DM, cardiovascular disease, non-alcoholic fatty liver disease, diabetic kidney disease, and obesity. These studies suggest that sCD36 could be a useful biomarker for metabolic diseases in children and a potential therapeutic target in preventing metabolic diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.